The treatment armamentarium for hepatitis C has seen a recent addition - a fixed-dose combination of sofosbuvir, velpatasvir and voxilaprevir, which has been approved by the U.S. Food and Drug Administration for the treatment of chronic hepatitis C without cirrhosis or with mild cirrhosis in previously treated patients.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer